Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
11 NC counties are under alert, including Johnston County.
Closings
1 closing/delay reported.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
1,145.03
-5.16 (-0.45%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
913,815
Open
1,145.99
Bid (Size)
1,143.00 (1)
Ask (Size)
1,170.00 (1)
Prev. Close
1,150.19
Today's Range
1,136.22 - 1,149.41
52wk Range
769.19 - 1,211.20
Shares Outstanding
91,779,465
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
Today 7:45 EDT
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
September 13, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Performance
YTD
+26.52%
+26.52%
1 Month
-3.96%
-3.96%
3 Month
+9.64%
+9.64%
6 Month
+18.29%
+18.29%
1 Year
+37.69%
+37.69%
More News
Read More
Time To Invest And Or Trade In Bio-Tech Stocks?
September 13, 2024
Via
Talk Markets
Topics
ETFs
Competitor Analysis: Evaluating Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
September 11, 2024
Via
Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $4,000 Today
September 10, 2024
Via
Benzinga
Beyond The Numbers: 20 Analysts Discuss Regeneron Pharmaceuticals Stock
September 09, 2024
Via
Benzinga
Evaluating Regeneron Pharmaceuticals Against Peers In Biotechnology Industry
August 27, 2024
Via
Benzinga
Biotech Breakout: Stocks for Your Watchlist
September 12, 2024
Via
MarketBeat
Topics
ETFs
Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease
September 11, 2024
Via
Benzinga
MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits
September 11, 2024
Via
News Direct
EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile
September 11, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
What Analysts Are Saying About Regeneron Pharmaceuticals Stock
August 23, 2024
Via
Benzinga
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $130 Thousand Today
August 20, 2024
Via
Benzinga
Prediction: These 2 Companies Will Split Their Stocks by 2027
September 11, 2024
Via
The Motley Fool
Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)
September 11, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial
September 11, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer
September 09, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO
September 09, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Prediction: These 2 Cathie Wood Stocks Could Crush the Market Through 2030
September 05, 2024
Via
The Motley Fool
Biotech And Life Science Sector Update Summer Of 2024
August 29, 2024
Via
Talk Markets
Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
August 26, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases
August 26, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
10 Bagger Stocks: Can You Find One?
August 23, 2024
Via
Talk Markets
Regeneron Faces Setback With FDA Rejection Of Blood-Cancer Treatment
August 20, 2024
Via
Benzinga
Exposures
Product Safety
Regeneron Provides Update on Biologics License Application for Linvoseltamab
August 20, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.